{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:12 23:20:22.323",
            "Expression": "mesenchymal ADSTEM Inj.",
            "NStudiesAvail": 430639,
            "NStudiesFound": 3,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 3,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "30902"
                        ],
                        "SecondaryIdDomain": [
                              "Republic or Korea Ministry of Food and Drug Safety"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Grant/Funding Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "TBSA, erythema, edema/papulation, oozing/crusting, excoriation, lichenification, dryness, pruritus, and insomnia"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The reduction ratio of scoring atopic dermatitis (SCORAD) index as contrasted with baseline value",
                              "The variation of SCORAD index as contrasted with baseline value",
                              "The variation of each index score of SCORAD index as contrasted with baseline value",
                              "The variation of the degrees of disease as contrasted with baseline value",
                              "The variation of investigator's global assessment (IGA) as contrasted with baseline value",
                              "The variation of eczema area and severity index (EASI) total score as contrasted with baseline value",
                              "The variation of total immunoglobulin E (IgE) in serum as contrasted with baseline value",
                              "The variation of total prostaglandin E2 (PGE2) in serum as contrasted with baseline value",
                              "The variation of total eosinophil cationic protein (ECP) in serum as contrasted with baseline value",
                              "The variation of total Chemokine ligand 17 (CCL17) in serum as contrasted with baseline value",
                              "The variation of total Chemokine ligand 27 (CCL27) in serum as contrasted with baseline value"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 weeks follow-up after treatment",
                              "12 weeks follow-up after treatment",
                              "12 weeks follow-up after treatment",
                              "12 weeks follow-up after treatment",
                              "12 weeks follow-up after treatment",
                              "12 weeks follow-up after treatment",
                              "12 weeks follow-up after treatment",
                              "12 weeks follow-up after treatment",
                              "12 weeks follow-up after treatment",
                              "12 weeks follow-up after treatment",
                              "12 weeks follow-up after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02888704"
                        ]
                  },
                  {
                        "Rank": 2,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [
                              "Non-Probability Sample"
                        ],
                        "SecondaryId": [
                              "30902"
                        ],
                        "SecondaryIdDomain": [
                              "Republic or Korea Ministry of Food and Drug Safety"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Grant/Funding Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "The number of subjects with treatment-related adverse events"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Adverse events"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "60months after treatment of ADSTEM Inj."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03252340"
                        ]
                  },
                  {
                        "Rank": 3,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "30902"
                        ],
                        "SecondaryIdDomain": [
                              "Republic of Korea Ministry of Food and Durg Safety"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Grant/Funding Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Percentage of subjects whose EASI score decreased by 50% or more at 4, 8 and 12 weeks compared to baseline",
                              "Percentage of subjects whose EASI score decreased by 75% or more at 4, 8, 12 and 16 weeks compared to baseline",
                              "EASI score change at 4, 8, 12 and 16 weeks compared to baseline",
                              "Percentage of subjects whose SCORAD score decreased by 50% or more at 4, 8, 12 and 16 weeks compared to baseline",
                              "Percentage of subjects whose SCORAD score decreased 75% or more at 4, 8, 12 and 16 weeks compared to baseline",
                              "SCORAD score change at 4, 8, 12 and 16 weeks compared to baseline",
                              "SCORAD evaluation items(Extent Criteria, erythema, edema/population, oozing/crusting, excoriation, lichenification, dryness, pruritus, insomnia) score change at 4, 8, 12 and 16 weeks compared to baseline",
                              "Severity change of disease at 4, 8, 12 and 16 weeks compared to baseline",
                              "Investigator's Global Assessment (IGA) score at 4, 8, 12 and 16 weeks compared to baseline",
                              "Percentage of subjects who dropped one or more grades on the Investigator's Global Assessment (IGA) score at 4, 8, 12 and 16 weeks compared to baseline",
                              "Percentage of subjects who dropped two or more grades on the Investigator's Global Assessment (IGA) score at 4, 8, 12 and 16 weeks compared to baseline",
                              "Total IgE change at 4, 8, 12, 16 weeks compared to baseline",
                              "Prostaglandin E2 (PGE2) and Eosinophil Cationic Protein (ECP) changes at 4, 8, 12 and 16 weeks compared to baseline",
                              "TGF-1, interleukin (IL)-4, 5, 6, 8, 13, 31 and CCL17 at 4, 8, 12 and 16 weeks compared to baseline",
                              "Days and frequency of used remedies at 4, 8, 12 and 16 weeks",
                              "Percentage of subjects whom used remedies at 4, 8,12 and 16 weeks"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "EASI-50",
                              "EASI-75",
                              "EASI score",
                              "SCORAD-50",
                              "SCORAD-75",
                              "SCORAD score",
                              "SCORAD subgroup",
                              "Severity",
                              "IGA grade",
                              "IGA -1 or more grade",
                              "IGA -2 or more grade",
                              "Total IgE",
                              "PGE2 and ECP",
                              "Immune cytokine",
                              "Remedy used days and frequency",
                              "Remedy used subjects"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "4, 8, 12 weeks",
                              "4, 8, 12, 16 weeks",
                              "4, 8, 12, 16 weeks",
                              "4, 8, 12, 16 weeks",
                              "4, 8, 12, 16 weeks",
                              "4, 8, 12, 16 weeks",
                              "4, 8, 12, 16 weeks",
                              "4, 8, 12, 16 weeks",
                              "4, 8, 12, 16 weeks",
                              "4, 8, 12, 16 weeks",
                              "4, 8, 12, 16 weeks",
                              "4, 8, 12, 16 weeks",
                              "4, 8, 12, 16 weeks",
                              "4, 8, 12, 16 weeks",
                              "4, 8, 12, 16 weeks",
                              "4, 8, 12, 16 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04137562"
                        ]
                  }
            ]
      }
}